A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine
Status:
Completed
Trial end date:
2020-04-10
Target enrollment:
Participant gender:
Summary
This is a randomised, placebo controlled, double blind, crossover proof of concept study to
investigate the efficacy and safety of oral LAT8881 in acute migraine, with or without aura.